Related Experiment Videos
Overall Survival and Treatment Outcomes in Patients With Primary Biliary Cholangitis: A 10-Year Single-Center
Shunyapat Sirirattanakorn1, Tanita Suttichaimongkol2, Witsarut Manasirisuk2
1Department of Medicine, Faculty of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand.
Background And Aims:
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease predominantly affecting women, carrying significant risks of cirrhosis and liver failure. While ursodeoxycholic acid (UDCA) is the established treatment of choice, overall survival and long-term treatment outcomes in Thai PBC patients remain largely unstudied. This 10-year retrospective cohort study aimed to determine the overall survival and treatment response rates in patients with PBC in Thailand.
Methods:
We included 57 PBC patients with complete data who were followed at Srinagarind Hospital, Khon Kaen University (2014-2024). Diagnosis required fulfilling at least two standard criteria (biochemical cholestasis, positive antibodies, or histological features). The primary outcome was 10-year overall survival (OS); secondary outcomes included UDCA treatment response (evaluated using the Paris I, Paris II, and Rotterdam criteria) and survival differences based on UDCA dosage.
Results:
The cohort was predominantly female (80.7%) with a median age of 55.14 years at diagnosis. Cirrhosis was present in 31.6% at the baseline. The 10-year OS rate was high at 85.96%. UDCA response rates ranged from 52.63% (Paris II) to 77.19% (Paris I). Overall survival was significantly higher in UDCA responders across all criteria (e.g., Paris I: P = 0.004; Rotterdam: P < 0.0001). While UDCA over-optimal dosing (>15 mg/kg/day) showed a trend toward higher survival, this difference did not reach statistical significance (P = 0.077).
Conclusion:
Achieving a biochemical response to UDCA is a strong and reliable predictor of improved OS in Thai PBC patients. These findings confirm favorable long-term outcomes in this population and highlight that further investigation into the optimal UDCA dosing strategy is warranted.
